Lenalidomid Sun

Lenalidomide, the active ingredient in Lenalidomid Sun, is an immunomodulatory imide drug (IMiD) presented as an oral tablet for oral use. It is indicated for the treatment of certain blood cancers, including multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma, in adult patients with relapsed or refractory disease.

GNH USA supplies Lenalidomid Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Lenalidomide is employed in hematologic malignancies that involve abnormal plasma cell or lymphoid proliferation. - Multiple myeloma: reduces tumor burden and prolongs progression‑free survival. - Myelodysplastic syndromes with del(5q): improves blood counts and reduces transfusion dependence. - Mantle cell lymphoma: induces remission and extends overall survival.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may lead to dehydration. - Nausea: mild to moderate upset stomach. - Rash: skin redness or itching. - Constipation: difficulty passing stools. - Peripheral edema: swelling of the lower extremities.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly reduced neutrophil count increasing infection risk. - Hepatotoxicity: elevated liver enzymes or liver injury. - Secondary primary malignancies: emergence of new cancers. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Lenalidomid Sun, clinicians should observe several safety considerations to minimize risk. - Pregnancy contraindication: avoid use in pregnancy (Category X) and ensure effective contraception. - Thromboembolic risk: assess patient history and consider prophylactic anticoagulation. - Renal impairment: adjust monitoring and dosing in patients with reduced kidney function. - Hepatic dysfunction: evaluate liver function before initiation and monitor regularly. - Infection vigilance: monitor for signs of infection due to neutropenia. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Lenalidomide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce lenalidomide exposure (e.g., rifampin, carbamazepine). - Anticoagulants: increased risk of bleeding when combined with warfarin or direct oral anticoagulants.

Moderate Interactions (Monitor Closely): - Immunosuppressants: may enhance infection risk (e.g., cyclosporine, tacrolimus). - CYP2C19 inhibitors: potential modest increase in plasma levels (e.g., fluoxetine). - P‑glycoprotein substrates: may affect drug transport (e.g., digoxin). - Vaccines: live vaccines should be avoided during treatment.